JP2021191267A5 - - Google Patents

Info

Publication number

JP2021191267A5

JP2021191267A5 JP2021127299A JP2021127299A JP2021191267A5 JP 2021191267 A5 JP2021191267 A5 JP 2021191267A5 JP 2021127299 A JP2021127299 A JP 2021127299A JP 2021127299 A JP2021127299 A JP 2021127299A JP 2021191267 A5 JP2021191267 A5 JP 2021191267A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

composition according

subject

amino acid

seq

Prior art date

2021-08-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 15
• 150000001413 amino acids Chemical group 0.000 claims 9
• 102100022816 Hemojuvelin Human genes 0.000 claims 5
• 101000756823 Homo sapiens Hemojuvelin Proteins 0.000 claims 5
• XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 4
• 230000000694 effects Effects 0.000 claims 4
• 102000018511 hepcidin Human genes 0.000 claims 4
• 108060003558 hepcidin Proteins 0.000 claims 4
• 229940066919 hepcidin Drugs 0.000 claims 4
• 210000002966 serum Anatomy 0.000 claims 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
• 208000016286 Iron metabolism disease Diseases 0.000 claims 2
• 208000007502 anemia Diseases 0.000 claims 2
• 230000005764 inhibitory process Effects 0.000 claims 2
• 208000017667 Chronic Disease Diseases 0.000 claims 1
• 102000001554 Hemoglobins Human genes 0.000 claims 1
• 108010054147 Hemoglobins Proteins 0.000 claims 1
• 108060003951 Immunoglobulin Proteins 0.000 claims 1
• 102000008133 Iron-Binding Proteins Human genes 0.000 claims 1
• 108010035210 Iron-Binding Proteins Proteins 0.000 claims 1
• 102000004338 Transferrin Human genes 0.000 claims 1
• 108090000901 Transferrin Proteins 0.000 claims 1
• 208000020832 chronic kidney disease Diseases 0.000 claims 1
• 102000018358 immunoglobulin Human genes 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 229910052742 iron Inorganic materials 0.000 claims 1
• 230000010438 iron metabolism Effects 0.000 claims 1
• 239000012581 transferrin Substances 0.000 claims 1